Biomarin Pharmaceutical Inc.
0
0
0%

Financials

Income statement

Fundamentals currency is USD
Fiscal date Sep 2025 Jun 2025 Mar 2025 Dec 2024
Total reported revenue 661.5M 703.5M 635.0M 636.9M
Cost of revenue 119.4M 127.9M 129.2M 116.0M
Gross profit 542.1M 575.5M 505.9M 520.9M
Operating expense
Research & development 349.0M 137.5M 135.3M 147.9M
Selling general and admin 228.7M 198.0M 175.6M 227.2M
Other operating expenses
Operating income -39.8M 236.0M 190.8M 137.5M
Non operating interest income
Income 15.2M 16.0M 16.2M 15.1M
Expense 2.2M 2.3M 2.4M 1.9M
Other income expense 4.3M 4.1M -1.7M -5.9M
Pretax income -22.4M 253.9M 202.9M 144.6M
Tax provision 3.8M 48.9M 44.7M 38.1M
Net income -26.2M 205.0M 158.3M 106.5M
Basic EPS 1.3 1.0 0.7
Diluted EPS 1.2 1.0 0.6
Basic average shares 163.6M 162.8M 162.5M
Diluted average shares 168.0M 167.4M 167.5M
EBITDA -4.5M 272.0M 224.2M 166.6M
Net income from continuing op. -26.2M 205.0M 158.3M 106.5M
Minority interests
Preferred stock dividends
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Main market

Exchange is currently active.
Closing in 4 hours 50 minutes

12:44
00:00
08:55
17:35
23:59

Trading Hours (Monday - Friday):

Pre-market
08:00 - 08:55
Main market
08:55 - 17:35
Post-market
17:35 - 17:50
All times are displayed in the Europe/Vienna timezone (CET, UTC+01:00).